Kotaro Tokui

Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor

Minehiko Inomata, Tomonobu Kado, Seisuke Okazawa et al. · Anticancer Research · 2019 · 46 citations · Full text

Life Sciences, Immunology, Oncology +17

Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib

Minehiko Inomata, Ryuji Hayashi, Hiroaki Tanaka et al. · Molecular and Clinical Oncology · 2016 · 23 citations · Full text

Medicine, Oncology, Pharmacology +14

SIRT1 and FOXO1 mRNA expression in PBMC correlates to physical activity in COPD patients

Chihiro Taka, Ryuji Hayashi, Kazuki Shimokawa et al. · International Journal of COPD · 2017 · 23 citations · Full text

Medicine, Physiology, Aging +15

Lactate Dehydrogenase and Body Mass Index are Prognostic Factors in Patients with Recurrent Small Cell Lung Cancer Receiving Amrubicin

Minehiko Inomata, Ryuji Hayashi, Kotaro Tokui et al. · Tumori Journal · 2015 · 21 citations

Medicine, Oncology, Pharmacotherapy +13

Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy

Minehiko Inomata, Takahiro Hirai, Zenta Seto et al. · Pathology & Oncology Research · 2018 · 20 citations

Medicine, Oncology, Pharmacotherapy +12